Pathos AI secured $62 million in an oversubscribed Series C round, led by New Enterprise Associates. This funding will enable the startup to expand its team and accelerate its innovative drug development processes using AI technology.
Who to call at Pathos AI, and when
A new round usually means Pathos AI is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Pathos AI raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Pathos AI, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pathos AI. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Pathos AI
Location
600 W. CHICAGO AVE.
Chicago, Illinois, United States
About
Pathos is an AI-enabled biotechnology company focused on re-engineering drug development, leveraging the power of technology to bring precision medicine to patients through partnerships with pharmaceutical companies. Pathos has raised over $100 million to accelerate the development of precision medicines and to expand its platform, combining computational approaches across multimodal real-world data and patient-derived biological models.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pathos AI raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ChicagoBiotechnologyHealth CareArtificial IntelligenceTherapeuticsMachine LearningPharmaceuticalHealth Diagnostics